New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 7, 2014
07:12 EDTBAYRY, CGENCompugen achieves initial milestone in collaboration with Bayer HealthCare
Compugen Ltd. (CGEN) disclosed hat it has achieved the initial milestone in the cancer immunotherapy collaboration it entered last year with Bayer HealthCare (BAYRY). The collaboration provides for the development and commercialization of therapeutic antibodies against two checkpoint protein candidates discovered by Compugen. The milestone being announced today relates to the first preclinical milestone for one of two checkpoint protein candidates for which Compugen will receive a $1.2M payment out of the $30M potential milestone payments associated with joint preclinical research for the two programs. The collaboration and license agreement provides the framework for the research, development, and commercialization of antibody-based therapeutics for cancer immunotherapy against two novel Compugen-discovered immune checkpoint regulators. Under the terms of the agreement, Bayer and Compugen are jointly pursuing a preclinical research program for each of the two candidates. Subsequently, Bayer will have full control over further development and have worldwide commercialization rights for potential cancer therapeutics. Under the terms of the agreement, Compugen has received an upfront payment of $10M and is eligible to receive over $500M in potential milestone payments for both checkpoint programs, plus an additional $30M of potential milestone payments associated with joint preclinical research for the two programs. Compugen is also eligible to receive royalties on global net sales from any resulting products under the collaboration.
News For CGEN;BAYRY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 3, 2015
07:08 EDTBAYRYAmerican Society for Clinical Pharmacology and Therapeutics holds meeting
Subscribe for More Information
February 26, 2015
11:36 EDTBAYRYBayer sees FY15 sales EUR 46
The company expects positive currency effects on sales of about 3% compared with the previous year. Bayer plans to raise EBITDA before special items by a low- to mid-teens percentage, allowing for expected positive currency effects of about 2 percent. Bayer aims to increase core earnings per share by a low-teens percentage, allowing for expected positive currency effects of around 3%.
11:35 EDTBAYRYBayer reports FY14 net income EUR 3.43B vs. EUR 3.19B last year
Subscribe for More Information
06:30 EDTBAYRYBayer says flotation of MaterialScience 'proceeding on schedule'
Subscribe for More Information
February 20, 2015
07:23 EDTBAYRYAbbVie replaces Pfizer as top global pharma pick at Jefferies
Subscribe for More Information
06:29 EDTBAYRYBayer close to selling diabetes unit to Panasonic, Bloomberg says
Subscribe for More Information
February 19, 2015
18:25 EDTBAYRYPiper Jaffray biotech analyst to hold analyst/industry conference call
Subscribe for More Information
16:50 EDTBAYRYSanofi appoints Olivier Brandicourt CEO
Subscribe for More Information
14:53 EDTBAYRYBayer near sale of diabetes unit to KKR backed venture, Bloomberg says
Subscribe for More Information
14:01 EDTBAYRYBayer near sale of diabetes unit to KKR's Panasonic Healthcare, Bloomberg says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use